Anika Appoints James Loerop as Executive Vice President of Business Development and Strategic Planning
July 08 2019 - 8:00AM
Business Wire
Industry veteran brings extensive experience
leading business development groups
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated
orthopedic and regenerative medicines company specializing in
therapeutics based on its proprietary hyaluronic acid ("HA")
technology, today announced the appointment of James Loerop to the
newly created position of Executive Vice President of Business
Development and Strategic Planning. Mr. Loerop is a 30-year
industry veteran with extensive expertise in business and corporate
development within the biopharma sector. In this new role, Mr.
Loerop will oversee the Company’s global business development
function, which will include balanced and disciplined management of
any new strategic business opportunities, initiatives, mergers,
acquisitions, partnerships, alliances, and licensing
agreements.
“As part of our continued efforts to transform Anika into a
global commercial company, we are pleased to welcome Mr. Loerop to
our executive leadership team to lead our business development
strategy,” said Joseph Darling, President and Chief Executive
Officer of Anika Therapeutics. “Jim’s depth of knowledge and
experience will be instrumental to the refinement and execution of
our long-term growth strategy, which will include identifying
partnership opportunities to expand our commercial portfolio and
global footprint.”
“I am excited to lead Anika’s business development team during
this critical phase in its evolution into a global commercial
company,” said James Loerop, Executive Vice President of Business
Development and Strategic Planning at Anika Therapeutics. “I
believe Anika is in a unique position to leverage its innovative
technology platform, diverse and expansive commercial portfolio and
legacy of fiscal responsibility to forge partnerships and
collaborations that will advance its near- and long-term
goals.”
Most recently, Mr. Loerop served as the Chief Corporate
Development Officer at Lupin Pharmaceuticals, a global
pharmaceutical company offering a wide range of products such as
branded & generic formulations, biotechnology products, active
pharmaceutical ingredients (APIs) and specialty products.
Previously, Mr. Loerop held leadership positions with Alexion
Pharmaceuticals, GlaxoSmithKline, and Steifel Laboratories, where
he led business development teams through numerous corporate
development initiatives, including numerous acquisitions. He holds
a Bachelor of Science in Marketing from Western Michigan
University. Click here to view Mr. Loerop’s full bio.
About Anika Therapeutics, Inc. Anika Therapeutics, Inc.
(NASDAQ: ANIK) is a global, integrated orthopedic and regenerative
medicines company based in Bedford, Massachusetts. Anika is
committed to improving the lives of patients with degenerative
orthopedic diseases and traumatic conditions with clinically
meaningful therapies along the continuum of care, from palliative
pain management to regenerative tissue repair. The Company has over
two decades of global expertise developing, manufacturing, and
commercializing more than 20 products based on its proprietary
hyaluronic acid (HA) technology. Anika's orthopedic medicine
portfolio includes ORTHOVISC®,
MONOVISC®, and CINGAL®, which alleviate
pain and restore joint function by replenishing depleted HA, and
HYALOFAST, a solid HA-based scaffold to aid cartilage repair
and regeneration. For more information about Anika, please visit
www.anikatherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190708005116/en/
For Investor Inquiries: Anika Therapeutics, Inc. Sylvia Cheung,
781-457-9000 Chief Financial Officer
For Media Inquiries: W2O Group Sonal Vasudev, 917-523-1418
sonal@w2ogroup.com
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Apr 2023 to Apr 2024